Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claire Feeney

Showing results (21-30 of 34) with videos related to

Pageof 4
Sort By:
American Journal of Clinical Dermatology|December 13, 2022
Early Itch Response with Abrocitinib Is Associated with Later Efficacy Outcomes in Patients with Moderate-to-Severe Atopic Dermatitis: Subgroup Analysis of the Randomized Phase III JADE COMPARE TrialSonja Ständer, Shawn G Kwatra, Jonathan I Silverberg, et al.
Thyroid Research|July 21, 2025
Predictive demographic and clinical features for the development of dysthyroid optic neuropathy in a multi-ethnic TED population: a retrospective cohort studyMalik Moledina, Vickie Lee, Ahmed Alnahrawy, et al.
JAMA Dermatology|August 18, 2021
Efficacy and Safety of Abrocitinib in Combination With Topical Therapy in Adolescents With Moderate-to-Severe Atopic Dermatitis: The JADE TEEN Randomized Clinical TrialLawrence F Eichenfield, Carsten Flohr, Robert Sidbury, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 29, 2016
Kinetic analysis of the translocator protein positron emission tomography ligand [<sup>18</sup>F]GE-180 in the human brainClaire Feeney, Gregory Scott, Joel Raffel, et al.
Annals of Neurology|June 25, 2013
Pituitary dysfunction after blast traumatic brain injury: The UK BIOSAP studyDavid Baxter, David J Sharp, Claire Feeney, et al.
American Journal of Clinical Dermatology|May 22, 2023
Efficacy and Safety of Abrocitinib in Patients with Severe and/or Difficult-to-Treat Atopic Dermatitis: A Post Hoc Analysis of the Randomized Phase 3 JADE COMPARE TrialEric L Simpson, Jonathan I Silverberg, Jacob P Thyssen, et al.
Dermatology and Therapy|September 23, 2025
Do Allergic Comorbidities Alter the Efficacy and Safety of Abrocitinib or Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis?Eric L Simpson, Jonathan I Silverberg, Bob Geng, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|September 2, 2017
The screening and management of pituitary dysfunction following traumatic brain injury in adults: British Neurotrauma Group guidanceChin Lik Tan, Seyed Alireza Alavi, Stephanie E Baldeweg, et al.
Lancet (London, England)|July 27, 2020
Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trialEric L Simpson, Rodney Sinclair, Seth Forman, et al.
Annals of Neurology|June 3, 2017
Serum insulin-like growth factor-I levels are associated with improved white matter recovery after traumatic brain injuryClaire Feeney, David J Sharp, Peter J Hellyer, et al.
Pageof 4

Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
American Journal of Clinical Dermatology|December 13, 2022
Early Itch Response with Abrocitinib Is Associated with Later Efficacy Outcomes in Patients with Moderate-to-Severe Atopic Dermatitis: Subgroup Analysis of the Randomized Phase III JADE COMPARE TrialSonja Ständer, Shawn G Kwatra, Jonathan I Silverberg, et al.
Thyroid Research|July 21, 2025
Predictive demographic and clinical features for the development of dysthyroid optic neuropathy in a multi-ethnic TED population: a retrospective cohort studyMalik Moledina, Vickie Lee, Ahmed Alnahrawy, et al.
JAMA Dermatology|August 18, 2021
Efficacy and Safety of Abrocitinib in Combination With Topical Therapy in Adolescents With Moderate-to-Severe Atopic Dermatitis: The JADE TEEN Randomized Clinical TrialLawrence F Eichenfield, Carsten Flohr, Robert Sidbury, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 29, 2016
Kinetic analysis of the translocator protein positron emission tomography ligand [<sup>18</sup>F]GE-180 in the human brainClaire Feeney, Gregory Scott, Joel Raffel, et al.
Annals of Neurology|June 25, 2013
Pituitary dysfunction after blast traumatic brain injury: The UK BIOSAP studyDavid Baxter, David J Sharp, Claire Feeney, et al.
American Journal of Clinical Dermatology|May 22, 2023
Efficacy and Safety of Abrocitinib in Patients with Severe and/or Difficult-to-Treat Atopic Dermatitis: A Post Hoc Analysis of the Randomized Phase 3 JADE COMPARE TrialEric L Simpson, Jonathan I Silverberg, Jacob P Thyssen, et al.
Dermatology and Therapy|September 23, 2025
Do Allergic Comorbidities Alter the Efficacy and Safety of Abrocitinib or Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis?Eric L Simpson, Jonathan I Silverberg, Bob Geng, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|September 2, 2017
The screening and management of pituitary dysfunction following traumatic brain injury in adults: British Neurotrauma Group guidanceChin Lik Tan, Seyed Alireza Alavi, Stephanie E Baldeweg, et al.
Lancet (London, England)|July 27, 2020
Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trialEric L Simpson, Rodney Sinclair, Seth Forman, et al.
Annals of Neurology|June 3, 2017
Serum insulin-like growth factor-I levels are associated with improved white matter recovery after traumatic brain injuryClaire Feeney, David J Sharp, Peter J Hellyer, et al.
Pageof 4